In our study, due to the differences in the signs, medical history and laboratory examination of patients with GBC and cholecystitis, as well as the diagnostic ability of metabolic parameters of 18F-FDG PET, we combined clinical variables, including cholecystolithiasis, fever, CEA > 5 ng/ml, and SUVR, to form a differential diagnostic model. This evidence concerns the gene CEACAM5 and Cholecystitis.